(3) hours of CME to include all 4 of the following topics: 1) best practices for the prescribing of CDS, 2) drug diversion training, 3) appropriate treatment for addiction, and 4) the treatment of chronic pain (one-time requirement for practitioners with a Controlled Dangerous Substance license; as of 1/1/2025, the only approved course is offered through the Board).

(8) hours on treating and managing patients with opioid or other substance use disorders, including the appropriate clinical use of all FDA-approved drugs for the treatment of a substance use disorder. This is a one-time requirement for all DEA-registered practitioners (with the exception of DVM-only license holders), beginning with DEA initial or renewal registrations starting June 27, 2023.

For more information:
https://www.lsbme.la.gov/content/board-approved-cme-courses-cds-requirements

(3) hours to include all 4 of the following topics: 1) best practices for the prescribing of CDS, 2) drug diversion training, 3) appropriate treatment for addiction, and 4) the treatment of chronic pain (one-time requirement for practitioners with a Controlled Dangerous Substance license; as of 1/1/2025, the only approved course is offered through the Board).

(6) contact hours of CE in pharmacotherapeutics in their advanced nursing role and population foci (annually).

(8) hours on treating and managing patients with opioid or other substance use disorders, including the appropriate clinical use of all FDA-approved drugs for the treatment of a substance use disorder. This is a one-time requirement for all DEA-registered practitioners (with the exception of DVM-only license holders), beginning with DEA initial or renewal registrations starting June 27, 2023.

For more information:
https://www.lsbn.state.la.us/continuing-education-2/

(3) hours of CME to include all 4 of the following topics: 1) best practices for the prescribing of CDS, 2) drug diversion training, 3) appropriate treatment for addiction, and 4) the treatment of chronic pain (one-time requirement for practitioners with a Controlled Dangerous Substance license; as of 1/1/2025, the only approved course is offered through the Board).  

(8) hours on treating and managing patients with opioid or other substance use disorders, including the appropriate clinical use of all FDA-approved drugs for the treatment of a substance use disorder. This is a one-time requirement for all DEA-registered practitioners (with the exception of DVM-only license holders), beginning with DEA initial or renewal registrations starting June 27, 2023.

For more information:
https://www.lsbme.la.gov/content/board-approved-cme-courses-cds-requirements